Spots Global Cancer Trial Database for FLX475 in Combination With Ipilimumab in Advanced Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: FLX475 in Combination With Ipilimumab in Advanced Melanoma
Official Title: Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma
Study ID: NCT04894994
Conditions
Study Description
Brief Summary: This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, Los Angeles, Los Angeles, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: William Ho, MD, PhD
Affiliation: RAPT Therapeutics, Inc.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
